Perifolliculitis Capitis Abscedens Et Suffodiens Treatment With Tumor Necrosis Factor Inhibitors and Baricitinib: A Case Report and Literature Review

March 2023 in “ Frontiers in medicine ”

Yuanting Yu, Xiaojie Ding, Fei Guo, Ze Kan, Xinghuai Sun, Xin Li

perifolliculitis capitis abscedens et suffodiens adalimumab baricitinib isotretinoin tumor necrosis factor inhibitors inflammatory alopecia Humira Olumiant Accutane TNF inhibitors

Studysummary This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months. Our plain-language summary of this paper — not a Tressless recommendation.

A 15-year-old boy with perifolliculitis capitis abscedens et suffodiens (PCAS) was treated with a combination of adalimumab and baricitinib after initial treatment with adalimumab and isotretinoin proved insufficient. Over 9 months, the patient's condition significantly improved, with almost complete healing of skin lesions and disappearance of most inflammatory alopecia patches. This case represents the first documented successful treatment of PCAS using tumor necrosis factor inhibitors and baricitinib, as no previous reports were found in the literature.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

66 citations , June 2021 in “Journal of The American Academy of Dermatology”

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

Dissecting Cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): A Comprehensive Review Focusing on New Treatments and Findings of the Last Decade with Commentary Comparing the Therapies and Causes of Dissecting Cellulitis to Hidradenitis Suppurativa

research Dissecting Cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): A Comprehensive Review Focusing on New Treatments and Findings of the Last Decade with Commentary Comparing the Therapies and Causes of Dissecting Cellulitis to Hidradenitis Suppurativa

48 citations , January 2014 in “Dermatology Online Journal”

This review examines various treatments for dissecting cellulitis, noting isotretinoin may offer the best chance for remission despite limited long-term data and calls for more clinical studies.